Hervé Dombret, MD, of Hopital Saint Louis in Paris, describes a phase 3 trial that compared azacitadine with conventional care (including intensive chemotherapy and best supportive care) in older patients with acute myeloid leukemia. The study, presented at the European Hematology Association meeting in Milan, showed a median gain of about four months in overall survival with azacitadine.
You are here
Azacitadine Extends Survival in Acute Myeloid Leukemia
European Hematology Association
Managed Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T. Search for "Managed Care," "Pharmacy and Therapeutics," or "MediMedia."